Genitourinary tract neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Genitourinary tract neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Using Indocyanine Green Fluorescence Imaging to Help Surgeons Better Identify Tumor Edges During Cancer Surgery in Patients with Solid Tumors https://clinicaltrials.eu/trial/a-study-using-indocyanine-green-fluorescence-imaging-to-help-surgeons-better-identify-tumor-edges-during-cancer-surgery-in-patients-with-solid-tumors/ Wed, 29 Apr 2026 15:08:23 +0000 https://clinicaltrials.eu/trial/a-study-using-indocyanine-green-fluorescence-imaging-to-help-surgeons-better-identify-tumor-edges-during-cancer-surgery-in-patients-with-solid-tumors/ This clinical trial is studying various types of solid malignancy, which means cancers that form solid tumors rather than blood cancers. These include cancers of the head and neck, digestive system, liver and bile ducts, breast, urinary and reproductive organs, and sarcomas, which are cancers that develop in bones or soft tissues like muscles and fat. The treatment being used in this study is indocyanine green, a substance that glows under special light and is given through a vein. The medicine being studied is called VERDYE, which contains indocyanine green as its active ingredient.

The purpose of this study is to find the best amount and timing of indocyanine green to create enough difference in brightness between the tumor and normal tissue, and to check whether this glowing effect can help surgeons accurately identify the edges of tumors during surgery. The study will look at how well the fluorescence imaging, which is a technique that uses special cameras to see the glowing substance, matches with what is found when tissue is examined under a microscope after removal. Researchers will also count how many additional glowing areas are found and confirmed to be cancer, as well as cases where the glow incorrectly suggests cancer when there is none or misses cancer that is present.

During the study, patients who are already planned to have surgery to remove their cancer will receive an infusion of indocyanine green before or during their operation. Surgeons will use special cameras that can detect the fluorescence to look at the tumor area and the surrounding tissue. The removed tissue and any lymph nodes will be examined both with the fluorescence camera and later under a microscope to compare the results. The study will measure the brightness difference between tumor and normal tissue, check whether the edges of the removed tissue are free of cancer cells, and record any side effects that occur. The goal is to determine if this imaging method can help surgeons remove cancer more completely while preserving healthy tissue.

]]> Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy https://clinicaltrials.eu/trial/study-on-niraparib-for-patients-with-advanced-urothelial-cancer-after-initial-platinum-chemotherapy/ Wed, 29 Apr 2026 15:02:38 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-for-patients-with-advanced-urothelial-cancer-after-initial-platinum-chemotherapy/ This clinical trial is focused on studying urothelial cancer, a type of cancer that affects the lining of the bladder and other parts of the urinary system. The study is investigating the use of a medication called niraparib, which is taken as a hard capsule. Niraparib is being compared to the best supportive care, which means providing the best possible care without using the study medication, to see if it can help maintain the condition of patients whose cancer has not worsened after initial chemotherapy treatment that included platinum-based drugs.

The purpose of the study is to determine if maintenance treatment with niraparib can effectively prolong the time patients live without their disease getting worse. Participants in the study will be randomly assigned to receive either niraparib or the best supportive care. The study will monitor patients over a period to see how long they remain free from disease progression and to assess their overall survival, quality of life, and any side effects they may experience.

Patients who have completed their first round of chemotherapy and have not seen their cancer progress are eligible to participate. The study will also look at how well patients respond to the treatment and how long these responses last. The trial aims to provide valuable information on whether niraparib can be a beneficial maintenance treatment for patients with advanced urothelial cancer.

]]>